Colinz Laboratories Ltd
₹ 68.6
-5.00%
04 Feb
- close price
About
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]
Key Points
- Market Cap ₹ 8.65 Cr.
- Current Price ₹ 68.6
- High / Low ₹ 88.7 / 36.1
- Stock P/E 17.6
- Book Value ₹ 39.2
- Dividend Yield 0.00 %
- ROCE 6.72 %
- ROE 5.43 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 46.4 to 36.9 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -2.81% over past five years.
- Company has a low return on equity of 5.73% over last 3 years.
- Working capital days have increased from 20.4 days to 72.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 5.84 | |
| 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.43 | |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.41 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 7.02% |
| 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.40 | |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.15 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.61 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | |
| 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.49 | |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.83 | 1.95 | 1.98 | 1.96 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 45% |
| 3 Years: | 20% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.36 |
| 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.66 | |
| 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 1.59 | |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
| 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.62 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.21 |
| 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 9.30 | |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.64 | 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | -1.45 | |
| 0.00 | 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | -0.23 | |
| -0.37 | 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | |
| Net Cash Flow | 0.27 | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 | -1.45 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Jan - Dear Sir, As required under Regulation 47(3) of SEBI (LODR), Regulations, 2015. Please find the attached News Paper Publication made towards our issued Quarterly Results …
-
Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
24 Jan - Board approved unaudited IND-AS results for quarter and nine months ended 31 Dec 2025; limited review attached.
-
Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
24 Jan - Colinz Laboratories approved unaudited Q3 and nine-month results for period ended 31 Dec 2025; limited review dated 24 Jan 2026.
- Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations, 2015. 17 Jan
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
17 Jan - Board approved sale of Sinnar factory undertaking to Hilsun Foods for Rs4,00,00,000; completion by 31 Mar 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
http://www.colinz.com/about.html
CLL is a manufacturer and exporter of pharmaceutical formulations for allopathic, ayurvedic, nutraceticals in dosage forms of tablets, capsules, ointments, creams, granules, liquid, orals, injectables, syrups, suppsitories, etc. It also has certain specialized products for Gynaecology, cardiology, gastroenterology, etc.